Streetbeat News

Revenues

BMRN

Analyst ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) show a mix of opinions, with a recent shift towards more bullish views. The average 12-month price target has increased to $100.73. Key financial indicators suggest challenges in profitability and efficiency, despite notable revenue growth.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 12:00 pm

FTRE

Fortrea Holdings (NASDAQ:FTRE) has been analyzed by four analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $37.00, with a high of $43.00 and a low of $33.00. Analyst actions include both upgrades and downgrades, reflecting diverse perspectives on the company's performance and market position. Fortrea, a contract research organization, has shown positive revenue growth and a strong net margin but faces challenges in ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 12:00 pm

LEGN

Legend Biotech (NASDAQ:LEGN) has received mixed analyst ratings over the past three months, with a total of 14 analysts offering their perspectives. The ratings include 8 bullish, 6 somewhat bullish, and no bearish views. The 12-month price targets suggest an average of $84.07, with a high of $87.00 and a low of $65.00, marking a 10.62% increase from the previous average of $76.00. The company's financial health shows significant revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 12:00 pm

LUNR

Intuitive Machines shares dropped following the announcement of Q1 financial results and FY24 revenue guidance that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:58 am

SDHC

Smith Douglas Homes (NYSE:SDHC) reported Q1 2024 earnings of $0.33 per share, missing the consensus estimate of $0.41 by 19.51%. However, their quarterly sales of $189.209M exceeded the estimate of $188.359M by 0.45%, marking a 12.53% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:49 am

LUNR

Intuitive Machines projects its FY24 revenue to be between $200M-$240M, falling short of the estimated $267.925M. The company also anticipates its Q1 ending cash balance to be adequate for funding operations throughout the year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:37 am

LUNR

Intuitive Machines (NASDAQ:LUNR) reported Q1 sales of $73.068M, surpassing the analyst consensus estimate of $55.900M by 30.71%. This represents a 300.68% increase from the $18.236M in sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:32 am

BITB

FBTC

GBTC

U.S. Bitcoin spot ETFs experienced a net inflow of $65.96 million, led by Fidelity Wise Origin Bitcoin Fund and Bitwise Bitcoin ETF, contrasting with outflows in Hong Kong's Bitcoin ETF market. Grayscale Bitcoin Trust saw no change.

Portfolio Pulse from Murtuza Merchant

May 14, 2024 | 11:18 am

OPTN

Optinose projects XHANCE net revenues for FY24 to be between $85M-$95M, with net revenue per prescription surpassing $230. Operating expenses are forecasted to be $95M-$101M, including $6M in stock-based compensation. The company anticipates positive GAAP income from operations for FY25.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:07 am

CSTL

Castle Biosciences has announced the expansion of evidence supporting the performance of its TissueCypher Barrett's Esophagus Test, which is designed to predict the future development of esophageal cancer. This development could potentially enhance the company's product portfolio and market position by providing a valuable tool for early detection and management of esophageal cancer risk.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:07 am